Sage Journals: Discover world-class research

Abstract

In stability analysis, the current Food and Drug Administration (FDA) recommended procedure for estimating the expiration dating period (shelf-life) of a drug is limited to a single package, single strength product. Since most drug products are manufactured with more than one strength and are marketed in more than one package, stability analyses must be carried out for every combination of package and/or strength. This paper proposes a generalization of the current FDA procedure to analyze the stability data from a multiple package and/or strength study. Monte Carlo simulation was used to address some issues with the current procedure and evaluate the proposed generalization procedure. The proposed procedure is illustrated by an application to a data set consisting of five batches and two packages. Statistical issues and problems with the current approach of concern to industrial statisticians and the generalization are also discussed.

Keywords

Analysis of covariance Batch Expiration dating period Package Strength

Get full access to this article

View all access options for this article.

References

Food and Drug Administration. Guideline for Submitting Documentation for the Stability of Human Drugs and Biologics. U.S. Department of Health and Human Services: Rockville, Maryland; 1987.

Federal Register. International Conference on Harmonization: Stability Testing of New Drugs Substances and Products; Guideline; Availability; Notice. 1994;48754–48759.

Fairweather

Lin

Roswitha

. Regulatory, design, analysis aspects of complex stability studies. J Pharma Sci. 1995;84:1322–1326.

Lin

Roswitha

. Stability of drugs. In Statistics in the Pharmaceutical Industry. 2nd edition. Buncher

Tsay

eds. New York: Marcel Dekker; 1993;419–444.

Bancroft

. Analysis and inference for incompletely specified models involving the use of preliminary test(s) of significance. Biometrics. 1964;20:427–442.

Lin

Tsong

. Determination of significance level for pooling data in stability studies. American Statistical Association 1991 Proceedings of the Biopharmaceutical Section. 1991; 195–201.

Chow

Liu

. Statistical Design and Analysis in Pharmaceutical Sciences. New York: Marcel Dekker; 1995.

Ahn

Chen

Lin

. Classification of batches in a stability study. American Statistical Association 1995 Proceedings of the Biopharmaceutical Section. 1995.

Lin

. Applicability of matrix and bracket approach to stability study design. American Statistical Association 1994 Proceedings of the Biopharmaceutical Section. 1994; 142–147.

10.

Shao

Chow

. Statistical inference in stability analysis. Biometrics. 1994;50:753–763.

11.

Ruberg

Stegeman

. Pooling data for stability studies: Testing the equality of batch degradation slopes. Biometrics. 1991;47:1059–1069.

12.

Ruberg

Hsu

. Multiple comparison procedures for pooling batches in stability studies. Technometrics. 1992;34:465–472.

13.

Chow

Shao

. Estimating drug shelf-life with random batches. Biometrics. 1991;47:1071–1079.

14.

Murphy

Weisman

. Using random slopes for estimating shelf-life. American Statistical Association 1990 Proceedings of the Biopharmaceutical Section. 1990; 196–200.

15.

Chen

Hwang

Tsong

. Estimation of the shelf-life of drugs with mixed effects models. J Biopharma Stat. 1995;5:131–140.

16.

Liu

Chow

. On the analysis of stability data. American Statistical Association 1992 Proceedings of the Biopharmaceutical Section. 1992;198–203.

17.

Chow

Liu

. Design and Analysis of Bioavailability and Bioequivalence Studies. New York: Marcel Dekker; 1992.

18.

Nordbrock

. Statistical comparison of stability study designs. J Biopharma Stat. 1992;2:91–113.

Shelf-Life Estimation for Multifactor Stability Studies *

Abstract

Keywords

Get full access to this article

References